Brind.

Thermo Fisher Scientific Inc. and Merck are major players in the residual DNA testing market as of August 5, 2025.

2 reports, 1 independent Updated Aug 5

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Thermo Fisher Scientific Inc. and Merck are major players in the residual DNA testing market as of August 5, 2025.

Who's involved

What this event is mainly about

Thermo Fisher Scientific Inc.Merck

Keep exploring

The entities involved

Thermo Fisher Scientific Inc.
multinational company providing scientific instrumentation

Nothing else this week.
Merck
public company in Indonesia
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13

Related events

Thermo Fisher Scientific Inc. and iSpecimen are two healthcare companies that are currently competing for market share.Aug 30

Coverage

Newest first; wire copies grouped

Aug 5GlobeNewswireResidual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing The residual DNA testing market is
Jul 21GlobeNewswireCell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030 The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion b